We finally found a way to slash the blood protein linked to heart attacks, but killing it didn't save lives. The experimental drug pelacarsen successfully reduced levels of lipoprotein(a) by approximately 78% in patients, yet failed to reduce cardiovascular events after five years. This stark result challenges the assumption that simply lowering this specific marker automatically translates to longer survival for patients.
Elevated lipoprotein(a) affects about 20% of the global population, representing roughly one billion people who are at higher risk for heart disease despite healthy lifestyles. Led by Cleveland Clinic cardiologist Steven Nissen, the study enrolled 8,350 adults with existing heart disease to test whether lowering this specific protein would prevent further complications. The sheer scale of the trial highlights how widespread this genetic risk factor is among those already battling cardiac issues.

Cardiovascular disease remains the leading cause of death in developed countries, claiming more than 900,000 American lives annually, driving the high stakes of this research. Drugmaker Novartis announced the study missed its primary goals, though they noted the data provides crucial evidence on the relationship between Lp(a) and heart disease. The failure suggests that high levels might just be a warning sign rather than the direct engine causing arterial damage.
Experts suggest the treatment needs to start earlier before arteries harden, or that we have misunderstood the root cause of these blockages entirely. If reducing the protein does not stop the plaque buildup, then the real enemy may lie elsewhere in the biological chain reaction. Will future therapies target the inflammation instead of the lipid itself?




